CL2012000948A1 - Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. - Google Patents
Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc.Info
- Publication number
- CL2012000948A1 CL2012000948A1 CL2012000948A CL2012000948A CL2012000948A1 CL 2012000948 A1 CL2012000948 A1 CL 2012000948A1 CL 2012000948 A CL2012000948 A CL 2012000948A CL 2012000948 A CL2012000948 A CL 2012000948A CL 2012000948 A1 CL2012000948 A1 CL 2012000948A1
- Authority
- CL
- Chile
- Prior art keywords
- idm
- atanol
- propinate
- hfa
- fluticasone
- Prior art date
Links
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 title 1
- 239000000443 aerosol Substances 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 title 1
- 229960002714 fluticasone Drugs 0.000 title 1
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229940071648 metered dose inhaler Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- PDEFQWNXOUGDJR-UHFFFAOYSA-M sodium;2,2-dichloropropanoate Chemical compound [Na+].CC(Cl)(Cl)C([O-])=O PDEFQWNXOUGDJR-UHFFFAOYSA-M 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 239000000080 wetting agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918150.4A GB0918150D0 (en) | 2009-10-16 | 2009-10-16 | Improved formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000948A1 true CL2012000948A1 (es) | 2012-12-14 |
Family
ID=41462451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000948A CL2012000948A1 (es) | 2009-10-16 | 2012-04-13 | Formulación es aerosol en suspensión que comprende fumarato de formoterol dihidratado y propinato de fluticasona hfa y un agente humectante,de preferencia atanol;inhalador de dosis medida (idm)que comprende una lata y una válvula de dosificación;lata para usarse en el idm,útil en asmay epoc. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20120263766A1 (enExample) |
| EP (2) | EP2488157B1 (enExample) |
| JP (2) | JP5818801B2 (enExample) |
| CN (1) | CN102573791B (enExample) |
| AU (1) | AU2010305695B2 (enExample) |
| BR (1) | BR112012008969B1 (enExample) |
| CA (1) | CA2776845C (enExample) |
| CL (1) | CL2012000948A1 (enExample) |
| CY (1) | CY1123918T1 (enExample) |
| DK (1) | DK2488157T3 (enExample) |
| ES (1) | ES2859629T3 (enExample) |
| GB (1) | GB0918150D0 (enExample) |
| HR (1) | HRP20210379T1 (enExample) |
| HU (1) | HUE054030T2 (enExample) |
| IL (2) | IL219162A0 (enExample) |
| LT (1) | LT2488157T (enExample) |
| MX (1) | MX372991B (enExample) |
| NZ (1) | NZ599900A (enExample) |
| PL (1) | PL2488157T3 (enExample) |
| PT (1) | PT2488157T (enExample) |
| RS (1) | RS61430B1 (enExample) |
| SI (1) | SI2488157T1 (enExample) |
| SM (1) | SMT202100150T1 (enExample) |
| WO (1) | WO2011045429A1 (enExample) |
| ZA (1) | ZA201202595B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100496608C (zh) * | 2001-03-30 | 2009-06-10 | 洁垢技术有限公司 | 药用气溶胶制剂 |
| GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| WO2013127738A1 (de) * | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Neue treibgashaltige tiotropium-formulierung |
| RU2678992C2 (ru) | 2012-04-11 | 2019-02-05 | Сипла Лимитед | Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат |
| GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| CN105963282B (zh) * | 2016-05-04 | 2019-04-19 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
| WO2018059390A1 (zh) * | 2016-09-29 | 2018-04-05 | 广东东阳光药业有限公司 | 药物组合物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| EP1366777B1 (en) | 1995-04-14 | 2005-06-15 | SmithKline Beecham Corporation | Metered dose inhaler for salmeterol |
| DE69622166T2 (de) | 1995-04-14 | 2003-04-03 | Smithkline Beecham Corp., Philadelphia | Dosierinhalator für albuterol |
| JPH101442A (ja) * | 1996-06-12 | 1998-01-06 | Taisho Pharmaceut Co Ltd | 鼻炎用点鼻薬 |
| EP1393721B1 (en) * | 1997-03-20 | 2008-11-26 | Schering Corporation | Dosage form of powder agglomerates |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| EE05167B1 (et) * | 2000-05-22 | 2009-06-15 | Chiesi Farmaceutici S.P.A. | Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele |
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU2001289126A1 (en) | 2000-09-18 | 2002-04-02 | Glaxo Group Limited | Metered dose inhaler can coated two or more times with fluorocarbon polymers |
| CN1635870A (zh) * | 2000-10-09 | 2005-07-06 | 3M创新有限公司 | 药用气雾剂制剂 |
| CN100496608C (zh) * | 2001-03-30 | 2009-06-10 | 洁垢技术有限公司 | 药用气溶胶制剂 |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| GB0201400D0 (en) * | 2002-01-22 | 2002-03-13 | Glaxo Group Ltd | Novel apparatus and process |
| EP1531866A1 (en) * | 2002-08-29 | 2005-05-25 | Cipla Ltd. | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| GB0323684D0 (en) * | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| GB0327727D0 (en) * | 2003-11-28 | 2003-12-31 | Quadrant Drug Delivery Ltd | Viral microparticles |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
-
2009
- 2009-10-16 GB GBGB0918150.4A patent/GB0918150D0/en not_active Ceased
-
2010
- 2010-10-15 AU AU2010305695A patent/AU2010305695B2/en active Active
- 2010-10-15 CN CN201080046305.6A patent/CN102573791B/zh active Active
- 2010-10-15 RS RS20210159A patent/RS61430B1/sr unknown
- 2010-10-15 NZ NZ599900A patent/NZ599900A/en unknown
- 2010-10-15 US US13/502,097 patent/US20120263766A1/en not_active Abandoned
- 2010-10-15 HR HRP20210379TT patent/HRP20210379T1/hr unknown
- 2010-10-15 WO PCT/EP2010/065569 patent/WO2011045429A1/en not_active Ceased
- 2010-10-15 PT PT107687600T patent/PT2488157T/pt unknown
- 2010-10-15 LT LTEP10768760.0T patent/LT2488157T/lt unknown
- 2010-10-15 MX MX2012004338A patent/MX372991B/es active IP Right Grant
- 2010-10-15 HU HUE10768760A patent/HUE054030T2/hu unknown
- 2010-10-15 SM SM20210150T patent/SMT202100150T1/it unknown
- 2010-10-15 JP JP2012533648A patent/JP5818801B2/ja active Active
- 2010-10-15 ES ES10768760T patent/ES2859629T3/es active Active
- 2010-10-15 EP EP10768760.0A patent/EP2488157B1/en active Active
- 2010-10-15 BR BR112012008969-2A patent/BR112012008969B1/pt active IP Right Grant
- 2010-10-15 SI SI201032050T patent/SI2488157T1/sl unknown
- 2010-10-15 DK DK10768760.0T patent/DK2488157T3/da active
- 2010-10-15 CA CA2776845A patent/CA2776845C/en active Active
- 2010-10-15 PL PL10768760T patent/PL2488157T3/pl unknown
- 2010-10-15 EP EP20213235.3A patent/EP3811928A1/en not_active Withdrawn
-
2012
- 2012-04-11 ZA ZA2012/02595A patent/ZA201202595B/en unknown
- 2012-04-13 CL CL2012000948A patent/CL2012000948A1/es unknown
- 2012-04-15 IL IL219162A patent/IL219162A0/en unknown
-
2015
- 2015-09-29 JP JP2015191177A patent/JP2016040286A/ja active Pending
-
2017
- 2017-03-21 US US15/464,879 patent/US20180296468A2/en not_active Abandoned
-
2019
- 2019-09-15 IL IL26936919A patent/IL269369A/en unknown
-
2021
- 2021-03-05 CY CY20211100190T patent/CY1123918T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201590179A1 (ru) | Комбинированная терапия copd | |
| CL2009000601A1 (es) | Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis. | |
| MX2012004338A (es) | Formulaciones mejoradas. | |
| CO2022012449A2 (es) | Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada | |
| BRPI1011229A2 (pt) | co-suspensão, inalador de dose medida, e, métodos de preparação de um inalador de dose medida, de dispensação respiratória de um agente ativo a um paciente, e para tratar de um paciente. | |
| UY30139A1 (es) | Formulacion farmaceuica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| WO2011076841A3 (en) | Combination therapy for copd | |
| ATE541603T1 (de) | Inhalator für pulverförmige substanzen | |
| JP2010132695A5 (enExample) | ||
| BRPI0905775A2 (pt) | composição farmacêutica para inalação, método de tratar uma condição respiratória, uso de aclidínio, aclidínio, formulação e dispositivo inalador | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| UY34838A (es) | Nueva forma de dosificación y formulación | |
| JP2014530231A5 (enExample) | ||
| GB201118188D0 (en) | Manufacture of medicinal aerosol canisters | |
| AR089597A1 (es) | Un inhalador | |
| MX2015007912A (es) | Inhalador de polvo seco y metodo de uso. | |
| EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
| MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
| CL2014003211A1 (es) | Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende | |
| IL201632A (en) | Use of Formoterol and Clomethazone Dipropionate-containing Preparations for the Preparation of Medication for Use in Acute Acute Episodes | |
| DK2089008T3 (da) | Formulationer til afgivelse via tryksatte, afmålte dosisinhalatorer omfattende en essentiel olie som suspensionsstabilisator | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| CO2022007719A2 (es) | Lata de acero inoxidable para inhaladores dosificadores presurizados | |
| Newhouse et al. | D34 AEROSOLIZED MEDICATIONS: SPECIFICATIONS AND TREATMENT CONSIDERATIONS: In Vitro Comparison Of Aerosol Characteristics Of Two Hfa Pmdi Formulations Used In Asthma And COPD With Inspirachamber® And Aerochamber Plus Flow-Vu® | |
| PH12014500440A1 (en) | Method for preparing metered dose sprayed inhaler for treating respiratory disease |